Synta Pharmaceuticals, Inc. (SNTA) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Roth Still Positive on Synta (SNTA) Following Q1 Results; Adjusts Certain Estimates
May 8, 2014 3:33 PM EDTRoth is adjusting estimates on Synta Pharmaceuticals Corp. (Nasdaq: SNTA) following the company's Q1 report. The firm maintains its Buy rating and $27 target price on the company.
Analyst Joseph Pantginis said, We are encouraged that the GALAXY-1 results show separation of the Kaplan-Meier curves, demonstrating favorable overall survival for chemosensitive patients on ganetespib + docetaxel versus docetaxel alone ... We believe these results bode well for and confirm the choice of... More
Synta Pharma (SNTA) Enters $40M At-The-Market Common Sales Agreement
May 8, 2014 6:52 AM EDTSynta Pharmaceuticals, Inc. (NASDAQ: SNTA) filed a registration with the U.S. SEC to sell, from time to time, up to $40 million of its common stock. With the filing, the company said:
We have entered into an at the market issuance... More
